{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Myeloma Minutes","title":"029 Belantamab Returns: A New Combination for First Relapse Myeloma","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/9ebaf4d3\"></iframe>","width":"100%","height":180,"duration":1383,"description":"This episode explains the new NICE-approved combination of belantamab, pomalidomide and dexamethasone for people whose myeloma has relapsed after first-line treatment, including benefits, side effects and how treatment decisions are made.\n📌Key Takeaways:\n\nThis new combination can keep myeloma under control for nearly three years after first relapse.\nEye side effects are common but closely monitored, reversible and manageable with dose changes.\nPatients now have real choice between tablet-based or injection-based combinations after relapse.\n\nFor extra content and more resources, please visit our website: https://www.themyelomaminutes.com/\nWe are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/\nThe Myeloma UK InfoLine is: 0800 980 3332\nThis podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns\n \nABOUT YOUR HOSTS\nDr. Jam Kothari\nDr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.\n \nDr. Sally Moore\nDr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and...","thumbnail_url":"https://img.transistorcdn.com/rD-uEWjDenF-XROyoth2QyT0dpCjh2HWCm0evlIF6_g/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8wNDJl/MDM4NjA4NWE3NDkx/OTRkYzVkYzYxODIx/ZWI4YS5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}